Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: The need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome

Cancer Investigation

Volumn 23, Issue 6, 2005, Pages 488-496

  Montillo, Marco ^a   Schinkoethe, Timo ^b   Elter, Thomas ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Alemtuzumab; B cell chronic lymphocytic leukemia; Minimal residual disease

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD5 ANTIGEN; CELL SURFACE MARKER; FLUDARABINE PHOSPHATE; GENOMIC DNA; IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; BONE MARROW PURGING; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL PRACTICE; CONSENSUS SEQUENCE; DRUG POTENTIATION; ERADICATION THERAPY; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; LEUKEMIA; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; FLOW CYTOMETRY; HUMANS; LEUKEMIA, B-CELL, CHRONIC; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION;

EID: 26844554346     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500201418     Document Type: Article

References (55)

1. Brugiatelli, M.; Claisse, J.F.; Lenormand, B.; et al. Long-term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level. Br. J. Haematol. 1997, 97 (1), 113-118.
2. Rai, K.R.; Peterson, B.L.; Appelbaum, F.R.; et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 2000, 343 (24), 1750-1757.
3. Johnson, S.; Smith, A.G.; Loffler, H.; et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996, 347, 1432-1438.
4. Leporrier, M.; Chevret, S.; Cazin, B.; et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001, 98 (8), 2319-2325.
5. Clavio, M.; Miglino, M.; Spriano, M.; et al. First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. Eur. J. Haematol. 1998, 61 (3), 197-203.
6. Robertson, L.E.; Huh, Y.O.; Butler, J.J.; et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992, 80 (1), 29-36.
7. Magnac, C.; Sutton, L.; Cazin, B.; et al. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol. Cell Ther. 1999, 41 (1), 13-18.
8. Cabezudo, E.; Matutes, E.; Ramrattan, M.; Morilla, R.; Catovsky, D. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 1997, 11 (11), 1909-1914.
9. Weiss, M.A. Novel treatment strategies in chronic lymphocytic leukemia. Curr. Oncol. Rep. 2001, 3 (3), 217-222.
10. Wierda, W.; O'Brien, S.; Albitar, M.; et al. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 2001, 98 (771a), Abstract 3210.
11. Huhn, D.; von Schilling, C.; Wilhelm, M.; et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001, 98 (5), 1326-1331.
12. Itala, M.; Geisler, C.H.; Kimby, E.; et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur. J. Haematol. 2002, 69 (3), 129-134.
13. Keating, M.J.; Flinn, I.; Jain, V.; et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99 (10), 3554-3561.
14. Lundin, J.; Kimby, E.; Bjorkholm, M.; et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100 (3), 768-773.
15. Rai, K.R.; Freter, C.E.; Mercier, R.J.; et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. 2002, 20 (18), 3891-3897.
16. Gilleece, M.H.; Dexter, T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993, 82, 807-812.
17. Heit, W.; Bunjes, D.; Wiesneth, M.; et al. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogenic bone marrow transplantation. Br. J. Haematol. 1986, 64, 479-486.
18. Dyer, M.J.; Hale, G.; Hayhoe, F.G.; Waldmann, H. Effects of Campath-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989, 73, 1431-1439.
19. Greenwood, J.; Clark, M.; Waldmann, H. Structural motifs involved in human IgG antibody effector functions. Eur. J. Immunol. 1993, 23, 1098-1104.
20. Rowan, W.; Tite, J.; Topley, P. ; Brett, S.J. Cross-linking of the Campath-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998, 95, 427-436.
21. Perz, J.; Topaly, J.; Fruehauf, S.; Hensel, M.; Ho, A.D. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk. Lymphoma 2002, 43 (1), 149-151.
22. Rossmann, E.D.; Lundin, J.; Lenkei, R.; Mellstedt, H.; Osterborg, A. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol. J. 2001, 2 (5), 300-306.
23. Huh, Y.O.; Keating, M.J.; Saffer, H.L.; Jilani, I.; Lerner, S.; Albitar, M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am. J. Clin. Pathol. 2001, 116 (3), 437-443.
24. Dyer, M.S.J.; Hale, G.; Marcus, R.; Waldmann, H. Remission induction in patients with lymphoid malignancies using unconjugated Campath-1H monoclonal antibodies. Leuk. Lymphoma 1990, 2, 179-193.
25. Ginaldi, L.; De Martinis, M.; Matutes, E.; et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res. 1998, 22 (2), 185-191.
26. Hale, G.; Xia, M.Q.; Tighe, H.P.; Dyer, M.J.; Waldmann, H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990, 35 (3), 118-127.
27. Osterborg, A.; Dyer, M.J.; Bunjes, D.; et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. 1997, 15 (4), 1567-1574.
28. Osterborg, A.; Fassas, A.S.; Anagnostopoulos, A.; et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol. 1996, 93 (1), 151-153.
29. Arnold, A.; Cossman, J.; Bakhshi, A.; et al. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N. Engl. J. Med. 1983, 309 (26), 1593-1599.
30. Cleary, M.L.; Chao, J.; Warnke, R.; Sklar, J. Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 1984, 81 (2), 593-597.
31. Diss, T.C.; Peng, H.; Wotherspoon, A.C.; Isaacson, P.G.; Pan, L. Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type. J. Pathol. 1993, 169 (3), 291-295.
32. Montillo, M.; Cafro, A.M.; Tedeschi, A.; et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002, 87 (7), 695-700.
33. Rawstron, A.C.; Kennedy, B.; Evans, P.A.; et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98 (1), 29-35.
34. Corradini, P.; Astolfi, M.; Cherasco, C.; et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997, 89 (2), 724-731.
35. Provan, D.; Bartlett-Pandite, L.; Zwicky, C.; et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996, 88 (6), 2228-2235.
36. Pfitzner, T.; Reiser, M.; Barth, S.; et al. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann. Hematol. 2002, 81 (5), 258-266.
37. Kantor, A.B. The development and repertoire of B-1 cells (CD5 B cells). Immunol. Today 1991, 12 (11), 389-391.
38. Stahlberg, A.; Aman, P.; Ridell, B.; Mostad, P.; Kubista, M. Quantitative real-time PCR method for detection of B-lymphocyte monoclonality by comparison of kappa and lambda immunoglobulin light chain expression. Clin. Chem. 2003, 49 (1), 51-59.
39. Vuillier, F.; Claisse, J.F.; Vandenvelde, C.; et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk. Lymphoma 1992, 7 (3), 195-204.
40. Vuillier, F.; Scott-Algara, D.; Dighiero, G. Extensive analysis of lymphocyte subsets in normal subjects by three-color immunofluorescence. Nouv. Rev. Fr. Hematol. 1991, 33 (1), 31-38.
41. Jennings, C.D.; Foon, K.A. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997, 90 (8), 2863-2892.
42. Maloum, K.; Sutton, L.; Baudet, S.; et al. Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia. Br. J. Haematol. 2002, 119 (4), 970-975.
43. Rezvany, M.R.; Lundin, J.; Edman, P.; et al. Long-term follow-up of lymphocyte subsets after subcutaneous alemtuzumab (MabCampath) treatment as primary therapy for B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100 (207a), Abstract 778.
44. Kennedy, B.; Rawstron, A.C.; Haynes, A.P.; et al. Eradication of detectable minimal disease with Campath-1H therapy results in prolonged survival in patients with refractory B-CLL. Blood 2001, 98 (367a), Abstract 1544.
45. Moreton, P.; Kennedy, B.; Rawstron, A.; Hillmen, P. The correlation between the eradication of minimal residual disease (MRD) following alemtuzumab for CLL and overall survival. Proc. Natl. Acad. Sci. U. S. A. 2004, 23 (572), Abstract 6566.
46. Kennedy, B.; Rawstron, A.; Carter, C.; et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002, 99 (6), 2245-2247.
47. Elter, T.; Borchmann, P.; Schulz, H.; Reiser, M.; Engert, A. Development of a new, four-weekly schedule (FluCam) with concomitant application of Campath-1H and fludarabine in patients with relapsed/ refractory CLL. Blood 2002, 100 (803a), Abstract 3169.
48. Montillo, M.; Tedeschi, A.; Cafro, A.M.; et al. Sequential subcutaneous administration of CAMPATH-1H as treatment of minimal residual disease in CLL patients responding to fludarabine (FAMP). Blood 2002, 100 (804a), Abstract 3175.
49. Montillo, M.; Tedeschi, A.; Rossi, E.; et al. Subcutaneous alemtuzumab for the treatment of residual disease in patients with CLL in clinical response to fludarabine phosphate. Hematol. J. 2003, 4 (133), Abstract 432.
50. Montillo, M.; Tedeschi, A.; Rossi, V.; et al. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia 2004, 18 (1), 57-62.
51. Frampton, J.E.; Wagstaff, A.J. Alemtuzumab. Drugs 2003, 63, 1229-1243.
52. Perkins, J.G.; Flynn, J.M.; Howard, R.S.; Byrd, J.C. Frequency and type of serious infections in fludarabine-refractory B-cell chronic 1lymphocyic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002, 94, 2033-2039.
53. Moreton, P.; Kennedy, B.; Rawstron, A.; Hillmen, P. Achieving a MRD negative response after alemtuzumab for CLL is the best predictor for prolonged survival. Blood 2003, 102 (Pt2), (391b), Abstract 5290.
54. O'Brien, S.M.; Kantarjian, H.M.; Thomas, D.A.; Cortes, J.; Giles, F.J.; Wierda, W.G.; Koller, C.A.; Ferrajoli, A.; Browning, M.; Lerner, S.; Albitar, M.; Keating, M. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003, 98, 2657-2663.
55. Wendtner, C.M.; Ritgen, M.; Schweighofer, C.D.; the German CLL Study Group; et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004, 18 (6), 1093-1101. [Apr. 8; Epub ahead of print].